AI주식인사이트AI Stock Insight
B

페니트리움바이오

187660KOSDAQ

61.0 / 100

Reference Date: 2026-09-08

Financial Score12.0 / 40
News Sentiment20.0 / 25
Momentum15.0 / 20
Disclosure14.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 67.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Penitrium Bio operates as a Contract Research Organization (CRO), providing comprehensive clinical trial services to pharmaceutical companies and biotech ventures, leveraging AI and big data for digital clinical trial technologies. The company also conducts Phase IV clinical trials to monitor drug safety and efficacy post-market approval and develops oncology treatments through its biotech business.

Number of Employees

110people

Average Salary

72.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
19.23Industry Average 1.200.0Point

16.0x industry avg (risky)

ROE
-105.34Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
3.59Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼17.1% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼153.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -79.0% (declining, 3yr)

Detailed News Sentiment

9 totalPositive 8Neutral 1Negative 0Average Sentiment Score 80

Detailed Momentum

52-week position3.0Point

52w lower range (25%)

Current 6,470Won52-week high 18,67052-week low 2,355
1-month return6.0Point

1m +67.18% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

10 totalPositive 2Neutral 8Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-04
  • Neutral주식등의대량보유상황보고서(일반)2026-09-04
  • Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (재발성 또는 불응성 진행성 고형암 임상 2a상 임상시험계획 숭인)2026-09-03
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-02
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-27